logo
Plus   Neg
Share
Email

Roche Submits SBLA To FDA For Tecentriq-Avastin For Liver Cancer

Genentech, a member of the Roche Group (RHHBY), said it submitted Supplemental Biologics License Application to the U.S. Food and Drug Administration for Tecentriq in combination with Avastin for the most common form of Liver Cancer.

The application was based on the results of the Phase III IMbrave150 study, which demonstrated that Tecentriq in combination with Avastin reduced the risk of death by 42% and reduced the risk of disease worsening or death, compared with sorafenib.

Tecentriq is a monoclonal antibody designed to bind with a protein called PD-L1. Tecentriq is designed to bind to PD-L1 expressed on tumor cells and tumor-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Walt Disney Co.'s streaming service Disney+ now has 50 million paid subscribers globally, with the company achieving the milestone within five months after its U.S. launch. WeWork's parent company, We Company, said it has filed a lawsuit against Japanese conglomerate SoftBank Group Corp. for failing to consummate a $3 billion tender offer for the company's shares. After WeWork's failed attempt at an initial public offering last year, SoftBank acquired a majority stake in the office sharing company in a bailout, severing most ties with WeWork co-founder Adam Neumann. Walgreens is expanding drive-thru testing for the coronavirus to fifteen new locations in seven states across the U.S. later this week. They include Arizona, Florida, Illinois, Kentucky, Louisiana, Tennessee and Texas. The drive-thru locations are part of Walgreens' collaboration with the administration, federal health agencies, and state and local authorities to expand access to COVID-19 testing.
Follow RTT
>